FDA approves Roche ’s Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome

Roche announced today that the US Food and Drug Administration (FDA) has approved Actemra/RoActemra ® (tocilizumab) intravenous injection for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in patients two years of age and older.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news